Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

246 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study.
Chevallier P, Robillard N, Charbonnier A, Raffoux E, Maury S, Carras S, Chabrot C, Fohrer C, Bernard M, Blade JS, Etienne A, Talmant P, Delaunay J, Guillaume T, Mohty M, Bene MC, Ifrah N, Dombret H. Chevallier P, et al. Among authors: guillaume t. Blood. 2012 Mar 15;119(11):2474-7. doi: 10.1182/blood-2011-11-390781. Epub 2012 Jan 20. Blood. 2012. PMID: 22267607 Free article. Clinical Trial.
Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
Chevallier P, Roland V, Mahé B, Juge-Morineau N, Dubruille V, Guillaume T, Vigouroux S, Moreau P, Milpied N, Garand R, Avet-Loiseau H, Harousseau JL. Chevallier P, et al. Among authors: guillaume t. Leuk Res. 2005 Sep;29(9):1003-7. doi: 10.1016/j.leukres.2005.02.005. Epub 2005 Apr 8. Leuk Res. 2005. PMID: 16038726
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R, Guillaume T, Avet-Loiseau H, Dmytruk N, Girault S, Milpied N, Ifrah N, Mohty M, Harousseau JL. Chevallier P, et al. Among authors: guillaume t. J Clin Oncol. 2008 Nov 10;26(32):5192-7. doi: 10.1200/JCO.2007.15.9764. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854573 Clinical Trial.
Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases.
Chevallier P, Robillard N, Houille G, Ayari S, Guillaume T, Delaunay J, Harousseau JL, Avet-Loiseau H, Mohty M, Garand R. Chevallier P, et al. Among authors: guillaume t. Leukemia. 2009 Apr;23(4):806-7. doi: 10.1038/leu.2008.303. Epub 2008 Oct 30. Leukemia. 2009. PMID: 18971949 No abstract available.
Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease.
Chevallier P, Robillard N, Ayari S, Guillaume T, Delaunay J, Mechinaud F, Avet-Loiseau H, Mohty M, Harousseau JL, Garand R. Chevallier P, et al. Among authors: guillaume t. Br J Haematol. 2008 Dec;143(5):744-6. doi: 10.1111/j.1365-2141.2008.07153.x. Br J Haematol. 2008. PMID: 19036018 Free article. No abstract available.
Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies.
Cahu X, Rialland F, Touzeau C, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Mohty M. Cahu X, et al. Among authors: guillaume t. Biol Blood Marrow Transplant. 2009 Dec;15(12):1531-7. doi: 10.1016/j.bbmt.2009.07.021. Epub 2009 Sep 25. Biol Blood Marrow Transplant. 2009. PMID: 19896076 Free article.
Human herpes virus 6 infection is a hallmark of cord blood transplant in adults and may participate to delayed engraftment: a comparison with matched unrelated donors as stem cell source.
Chevallier P, Hebia-Fellah I, Planche L, Guillaume T, Bressolette-Bodin C, Coste-Burel M, Rialland F, Mohty M, Imbert-Marcille BM. Chevallier P, et al. Among authors: guillaume t. Bone Marrow Transplant. 2010 Jul;45(7):1204-11. doi: 10.1038/bmt.2009.326. Epub 2009 Nov 23. Bone Marrow Transplant. 2010. PMID: 19935727
Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.
Malard F, Szydlo RM, Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Mohty M. Malard F, et al. Among authors: guillaume t. Biol Blood Marrow Transplant. 2010 Jan;16(1):28-34. doi: 10.1016/j.bbmt.2009.08.010. Epub 2009 Oct 1. Biol Blood Marrow Transplant. 2010. PMID: 20053329 Free article.
246 results